
Topic
Formulary Strategy
Tiering, exclusions, preferred products, step therapy, and how access teams prepare the evidence packet.

Pricing & Access· May 24, 2026 · 11 min read

Pricing & Access· May 23, 2026 · 10 min read
DOAC access landscape: Eliquis, Xarelto, Pradaxa, and Savaysa in 2026
By Ran Chen#DOAC#Coverage Access#Prior Authorization

Biosimilars· May 23, 2026 · 10 min read
Remicade biosimilars: FDA status, payer coverage, switching, and coding
By Ran Chen#Biosimilars#Coverage Access#Payer Policy

Biosimilars· May 22, 2026 · 9 min read
Avastin biosimilars: FDA status, interchangeability, payer coverage, and switching
By Ran Chen#Biosimilars#Oncology#Coverage Access

Pricing & Access· May 22, 2026 · 10 min read
Dupixent vs Ebglyss: label, access, and payer coverage compared
By Ran Chen#Immunology#Prior Authorization#Payer Policy

Pricing & Access· May 22, 2026 · 17 min read
New-to-market payer blocks: the first 180 days after approval

Biosimilars· May 22, 2026 · 10 min read
Rituxan biosimilars: FDA status, interchangeability, payer coverage, and switching
By Ran Chen#Biosimilars#Oncology#Coverage Access

Biosimilars· May 21, 2026 · 7 min read
Herceptin biosimilars: FDA status, payer coverage, coding, and switching
By Ran Chen#Biosimilars#Oncology#Coverage Access

Biosimilars· May 20, 2026 · 9 min read
Humira biosimilars compared: FDA status, interchangeability, payer coverage, and switching

Pricing & Access· May 20, 2026 · 10 min read
Mounjaro vs Zepbound: label, access, and payer coverage compared
By Ran Chen#GLP-1#Coverage Access#Prior Authorization